Strategic Pricing and Market Expansion Drive 10x Genomics Buy Rating
Leerink Partners Maintains 10x Genomics(TXG.US) With Buy Rating
TD Cowen Maintains 10x Genomics(TXG.US) With Hold Rating, Cuts Target Price to $18
TD Cowen Reaffirms Their Hold Rating on 10x Genomics (TXG)
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $21
10x Genomics Is Maintained at Overweight by Barclays
10x Genomics Analyst Ratings
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $21
Temporary Disruption at 10x Genomics: A Buy Rating Amidst Sales Force Realignment and Strong Product Fundamentals
Stifel Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $25
10x Genomics Price Target Maintained With a $30.00/Share by Stephens & Co.
10x Genomics Analyst Ratings
Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $20
A Quick Look at Today's Ratings for 10x Genomics(TXG.US), With a Forecast Between $24 to $46
10x Genomics: Hold Rating Amidst Q3 Revenue Shortfall and Growth Uncertainty
Analysts' Top Healthcare Picks: Alnylam Pharma (ALNY), 10x Genomics (TXG)
TD Cowen Keeps Their Hold Rating on 10x Genomics (TXG)
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Torex Gold Resources Analyst Ratings
Stephens & Co. Reiterates Overweight on 10x Genomics, Maintains $30 Price Target